Skip to Content

Fluocinolone ophthalmic Pregnancy and Breastfeeding Warnings

Fluocinolone ophthalmic is also known as: Iluvien, Retisert

Fluocinolone ophthalmic Pregnancy Warnings

Fluocinolone ophthalmic has been assigned to pregnancy category C by the FDA. Animal studies have revealed evidence of teratogenicity when corticosteroids are administered orally. In addition, fluocinolone administered subcutaneously to rabbits in doses 10,000 times the dose of fluocinolone intravitreal implant induced abortion at the end of gestation week 3 and beginning of gestational week 4. There are no controlled data in human pregnancy. Fluocinolone ophthalmic is only recommended for use in pregnancy when benefit outweighs risk.

See references

Fluocinolone ophthalmic Breastfeeding Warnings

There are no data on the excretion of fluocinolone ophthalmic into human milk. Systemic corticosteroids are excreted in human milk, and may suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects in the infant. The manufacturer recommends that caution be used when administering fluocinolone ophthalmic to nursing women.

See references

References for pregnancy information

  1. "Product Information. Retisert (fluocinolone ophthalmic)." Bausch and Lomb, Rochester, NY.

References for breastfeeding information

  1. "Product Information. Retisert (fluocinolone ophthalmic)." Bausch and Lomb, Rochester, NY.

See Also...

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.